Program

EDUCATIONAL SESSIONS

10:00 a.m.-11:30 a.m.

• SESSION 1: NATURAL PRODUCT-DERIVED AGENTS
  Chairperson: Dennis C. Liotta, Emory University, Atlanta, GA

  
  Title to be announced
  Dennis C. Liotta

  Use of Natural Products as the Scaffolds for the Design of Molecularly Targeted Agents for Cancer Treatment and Prevention
  Shaomeng Wang, University of Michigan, Ann Arbor, MI

  Sphingolipid Biodiversity and Cancer: An Endless Source of Surprises in Cell Regulation and Novel Strategies for Cancer Chemoprevention and Chemotherapy
  Alfred H. Merrill, Georgia Institute of Technology, Atlanta, GA

• SESSION 2: ADVANCED METHODS AND TECHNOLOGIES FOR BIOMARKER RESEARCH
  Chairperson: John D. Groopman, Johns Hopkins University, Baltimore, MD

  
  Title to be announced
  John D. Groopman

  A Genome-wide Association Study of Breast Cancer
  David J. Hunter, Harvard University, Boston, MA

  Systems Biology Driven in vitro Diagnostic and Measurement Technologies for Cancer
  James R. Heath, California Institute of Technology, Pasadena, CA

• SESSION 3: INFLAMMATION
  Chairperson: Tak W. Mak, Princess Margaret Hospital, Toronto, ON, Canada
  
  Title to be announced
  Tak W. Mak
  
  Macrophages Regulate Inflammation in the Tumor Microenvironment
  Jeffrey W. Pollard, Albert Einstein College of Medicine, Bronx, NY
  
  Additional Speaker to be announced

PROFESSIONAL ADVANCEMENT SESSION

Chairperson: Waun Ki Hong, UT M.D. Anderson Cancer Center, Houston, TX
11:30 a.m.–1:00 p.m.

Panelists to be announced

EDUCATIONAL SESSIONS

1:00 p.m.-2:30 p.m.

• SESSION 4: MOLECULAR MECHANISMS OF AGING - RELATIONSHIP TO CANCER PREVENTION
  Chairperson: Jerry W. Shay, UT Southwestern Medical Center, Dallas, TX 

  
  Aging and Cancer: Are Telomeres and Telomerase the Connection?
  Jerry W. Shay

  The Role of Genes in Protecting Against Age-related Disease in Cancer
  Nir Barzilai, Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY

  Interleukins at the Crossroad of Inflammation, Senescence, and Cancer
  Daniel S. Peeper, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  
  Translating Research in Aging to Clinical and Policy Settings
  Jeanne Mandelblatt, Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC

• SESSION 5: PRECLINICAL MODELS FOR AGENT DISCOVERY
  Chairperson: Haian Fu, Emory University School of Medicine, Atlanta, GA

  
  High-throughput Screen Technologies for New Agent Discovery at an Academic Setting
  Haian Fu

  Model Systems for the Discovery of Cancer Preventive and Therapeutic Agents
  Raymond C. Bergan, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

  The Development of Tractable Mouse Models to Study Therapeutic Response
  Michael T. Hemann, Massachusetts Institute of Technology, Cambridge, MA

• SESSION 6: BIOSPECIMEN AVAILABILITY
  Chairperson to be announced
  
  PLCO Biospecimen Resource for Etiologic and Early Marker Research
  Claire Zhu, National Cancer Institute-DCP, Bethesda, MD
  
  Additional Speakers to be announced

EDUCATIONAL SESSIONS

2:45 p.m.-4:15 p.m.

• SESSION 7: VITAMIN D - THE CANCER CONNECTION
  Chairperson: Michael F. Holick, Boston University School of Medicine, Boston, MA 

  
  Title to be announced
  Michael F. Holick

  Ecological and Other Studies Supporting a Role of Vitamin D in Reducing the Risk of Cancer and Increasing Survival with Cancer
  William B. Grant, Sunlight, Nutrition, and Health Research Center, San Francisco, CA

  Role of Vitamin D in Prevention of Cancer: Dose-Response Relationships
  Cedrick Garland, University of California at San Diego, La Jolla, CA

• SESSION 8: TECHNOLOGIES
  Chairperson: Frank L. Meyskens, Jr., University of California at Irvine, Orange, CA

  
  How Should We Optimize Technology to Allow Personalized Medicine?
  Frank L. Meyskens, Jr.

  Designing Life Chips and their Impact for the Prevention and Early Detection of Cancer
  Nancy L. Allbritton,  University of North Carolina, Chapel Hill, NC 

  Advanced Imaging Strategies for Prevention and Early Detection
  Orhan Nalcioglu, University of California at Irvine, Orange, CA

• SESSION 9: DESIGNING CLINICAL TRIALS TO ADDRESS SAFETY AND EFFICACY ENDPOINTS
  Chairperson: Jaye L. Viner, National Cancer Institute, Bethesda, MD
  
  Celecoxib Trials and Clinical Quandaries
  Jaye L. Viner
  
  Results of a Phase III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer
  Anita L. Sabichi, UT M.D. Anderson Cancer Center, Houston, TX

  Prevention of Non-Melanoma Skin Cancer with Celecoxib
  Craig A. Elmets, University of Alabama School of Medicine, Birmingham, AL

SPECIAL SESSION: NCI OPPORTUNITIES FOR JUNIOR INVESTIGATORS

Chairperson: Jonathan S. Wiest, National Cancer Institute, Bethesda, MD
4:30 p.m.-5:30 p.m.

Panelists:

• Jonathan S. Wiest
• Jessica M. Faupel-Badger, Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD
• Lester S. Gorelic, National Cancer Institute, Rockville, MD

Additional Panelists to be announced

OPENING PLENARY SESSION

6:00 p.m.-7:30 p.m.

DISTINGUISHED LECTURE ON TARGETS FOR CANCER PREVENTION
Prevention of Cervical Cancer in Current and Future Generations by HPV Vaccination and Other Approaches
Douglas R. Lowy, National Cancer Institute, Bethesda, MD

KEYNOTE ADDRESS
Cancer and Aging: Rival Demons?
Judith Campisi, Lawrence Berkeley National Laboratory, Berkeley, CA

OPENING RECEPTION

7:30 p.m.-9:00 p.m.

PLENARY SESSION 1: MOLECULAR TARGETS IN CANCER PREVENTION

Chairperson: Phillip A. Dennis, National Cancer Institute, Bethesda, MD
7:45 a.m.-9:45 a.m.

Genetic Opportunities for Colon Cancer Prevention
Sanford D. Markowitz, Case Western Reserve University, Cleveland, OH

Studies on Tumor- and Metastasis-initiating Cells in the Lung: Novel Targets for Lung Cancer Prevention?
Jonathan M. Kurie, UT M.D. Anderson Cancer Center, Houston, TX

Progress in the Targeted Prevention of Lung Cancer
Fadlo R. Khuri, Emory University Winship Cancer Institute, Atlanta, GA

The Role of Lung-derived Regulatory T cells in Kras-driven Lung Tumorigenesis
Phillip A. Dennis

CONCURRENT SESSIONS

10:00 a.m.-11:45 a.m.

• SESSION 1: PROSTATE CANCER PREVENTION
  Chairperson: William G. Nelson, V, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

  
  Genetic and Epigenetic Changes in Prostate Cancer as Targets for Prevention
  William G. Nelson, V
  
  Prostate Cancer Risk Reduction Through Lifestyle Change and Chemoprevention: New Insights from the Prostate Cancer Prevention Trial
  Alan Kristal, Fred Hutchinson Cancer Research Center, Seattle, WA

  The Prostate Cancer Prevention Trial: An Update on Pathology
  M. Scott Lucia, University of Colorado Denver School of Medicine, Aurora, CO
  
  
• SESSION 2: OVARIAN CANCER RISK REDUCTION
  Chairperson: Karen A. Johnson, National Cancer Institute, Bethesda, MA

  
  Genetic Testing for Ovarian Cancer Risk: Implications for Extending Risk Assessment
  Marc D. Schwartz, Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC

  Surgical Risk Reduction: Salpingo-oophorectomy for Prevention of BRCA-associated Ovarian/Primary Peritoneal Carcinoma
  Timothy R. Rebbeck, University of Pennsylvania Cancer Center, Philadelphia, PA

  Future Prospects for Targeted Reduction of Ovarian Cancer Risk
  Karen A. Johnson

• SESSION 3: HEMATOLOGIC MALIGNANCIES
  Chairperson: Nikhil C. Munshi, Dana-Farber Cancer Institute, Boston, MA
  
  Molecular Determinants and Progression Risk in MGUS
  Nikhil C. Munshi
  
  Immune Surveillance in MGUS: A Balance between Immune Effector and Regulatory T Cells?
  Qing Yi, UT M. D. Anderson Cancer Center, Houston, TX

SPECIAL SESSION: ACHIEVING THE POTENTIAL OF CHEMOPREVENTION

Chairpersons: Ernest T. Hawk, UT M.D. Anderson Cancer Center, Houston, TX and Frank L. Meyskens, Jr.,  University of California at Irvine, Orange, CA
12:00 p.m.-1:00 p.m.

How Health Communications Turned Cardiovascular Prevention into a Reality
Lisa Sparks, Chapman University, Orange, CA

Incenting Investment in Chemoprevention
Gregory A. Curt, AstraZeneca, Garrit Park, MD

Chemoprevention: Poised for Success
Peter Greenwald, National Cancer Institute, Bethesda, MD

CONCURRENT SESSIONS

1:00 p.m.-2:45 p.m.

• SESSION 4: EARLY PHASE CLINICAL TRIALS OF CANCER PREVENTIVE AGENTS
  Chairpersons: Eva Szabo, National Cancer Institute, Bethesda, MD, and Hsaio-Hui (Sherry) Chow, University of Arizona, Tucson, AZ

  
  Presurgical Trials in Chemoprevention Drug Development
  Howard H. Bailey, University of Wisconsin, Madison, WI

  Phase 1b Sulindac Study for Women at High Risk for Breast Cancer
  Patricia A. Thompson, University of Arizona, Tucson, AZ
  
  Randomized Phase II Trial of Budesonide in High-Risk Population with Undetermined Lung Nodules Detected at Screening Low Dose CT Scfan
  Giulia Veronesi, European Institute of Oncology, Milan, Italy
  
  Commentary and Discussion
  Hsaio-Hui (Sherry) Chow and Eva Szabo
  
  Additional Speakers to be announced

• SESSION 5: ER STRESS, AUTOPHAGY, PROTEIN HOMEOSTASIS, AND PROTEIN DEGRADATION
  Chairperson: Vassiliki Karantza-Wadsworth, The Cancer Institute of New Jersey, New Brunswick, NJ

  
  Autophagy and Mammary Tumorigenesis: Role of Metabolic and ER Stress Management
  Vassiliki Karantza-Wadsworth

  Modulating ER Stress-induced Autophagy to Cancer Control
  Xiao-Ming Yin, University of Pittsburgh, Pittsburgh, PA
  
  Additional Speakers to be announced

• SESSION 6: ENERGY BALANCE AND PHYSICAL ACTIVITY
  Chairperson: Lucile L. Adams-Campbell, Howard University, Washington, DC
  
  Obesity, Physical Activity, and Colon Polyps: Black Women's Health Study
  Lucile L. Adams-Campbell
  
  Fitness versus Fatness in Breast Cancer Risk and Prognosis
  Anne McTiernan, Fred Hutchinson Cancer Research Center, Seattle, WA
  
  Pediatric Obesity Research: A Transdisciplinary Approach
  Donna Spruijt-Metz, University of Southern California, Los Angeles, CA

PLENARY SESSION 2: INTERNATIONAL PREVENTION MECHANISMS

Chairperson: Christopher P. Wild, University of Leeds, Leeds, United Kingdom
3:00 p.m.-5:00 p.m.

Global Trends in Cancer Incidence - Priorities for Prevention
Michael J. Thun, American Cancer Society, Atlanta, GA

Cancer Screening in Developing Countries
Rengaswamy Sankaranarayanan, International Agency for Research on Cancer, Lyon, France

Foodborne Toxins in Developing Countries
Christopher P. Wild 

Nutrition and Cancer - What Have We Learned So Far?
Elio Riboli, Imperial College, London, United Kingdom

AACR-PREVENT CANCER FOUNDATION AWARD LECTURE

5:00 p.m.-6:00 p.m.

Awardee to be announced

POSTER SESSION A

6:00 p.m.-8:30 p.m.

PLENARY SESSION 3: TUMOR MICROENVIRONMENT / INFLAMMATION

Chairperson: Suzanne Ostrand-Rosenberg, University of Maryland Baltimore County, Baltimore, MD
7:45 a.m.-9:45 a.m.

Role of Stat3 in the Tumor Microenvironment
Hua Yu, City of Hope, Duarte, CA 

Inflammation-driven Myeloid-derived Suppressor Cells: Co-opting Anti-Tumor Immunity to Promote Tumor Progression
Suzanne Ostrand-Rosenberg 

Additional Speakers to be announced

CONCURRENT SESSIONS

10:00 a.m.-11:45 a.m.

• SESSION 7: PERSONALIZED ASSESSMENT ON CANCER RISK
  Chairperson: Xifeng Wu, UT M.D. Anderson Cancer Center, Houston, TX

  
  Personalized Prediction of Bladder Cancer Risk: An Integrative Approach
  Xifeng Wu

  Discriminatory Accuracy from SNPs in Models of Absolute Breast Cancer Risk
  Mitchell H. Gail, National Institutes of Health, Bethesda, MD
  
  Risk Prediction Model for Lung Cancer
  Margaret R. Spitz, UT M.D. Anderson Cancer Center, Houston, TX

• SESSION 8: EPIGENETICS AND GENOME-WIDE SCREENING
  Chairperson: Brian J. Reid, Fred Hutchinson Cancer Research Institute, Seattle, WA

  
  Genome-wide Association Studies
  Stephen J. Chanock, National Cancer Institute, Bethesda, MD

  Genomic and Epigenomic Progression in Barrett's Esophagus
  Brian J. Reid 

  Additional Speakers to be announced

• SESSION 9: INFECTION
  Chairperson: Maura L. Gillison, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
  
  Infections and Cancer: The Global Burden
  Maura L. Gillison
  
  Cancer and Infection: Lessons from Immune Deficient Populations
  Andrew Grulich, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
  
  Current Controversies in the Viral Etiology of Cancer
  Eric A. Engels, National Cancer Institute, Rockville, MD
  
  Molecular Methods for New Pathogen Discovery
  Huichen Feng, University of Pittsburgh Cancer Institute, Pittsburgh, PA

CONCURRENT SESSIONS

1:00 p.m.-2:45 p.m.

• SESSION 10: PANCREAS
  Chairperson: David A. Tuveson, CRUK Cambridge Research Institute, Cambridge, United Kingdom 

  
  Mouse Models to Prevent and Treat Pancreatic Cancer
  David A. Tuveson

  Gene-Environment Risk Factors to Understand and Prevent Pancreatic Cancer in High Risk Kindreds
  Gloria M. Peterson, Mayo Clinic, Rochester, MN
  
  Anatomic Detection and Early Surgery to Prevent Pancreatic Cancer in High Risk Kindreds
  Michael G. Goggins, Johns Hopkins University, Baltimore, MD

• SESSION 11: CANCER HEALTH DISPARITIES
  Chairperson: Deborah J. Bowen, Boston University, Boston, MA

  
  Title to be announced
  Deborah J. Bowen

  Disparities in Mental Health Outcomes between Rural and Nonrural Cancer Survivors
  Michael A. Andrykowski, University of Kentucky, Lexington, KY
  
  Determinants of Cancer Disparities
  Chanita Hughes Halbert, University of Pennsylvania, Philadelphia, PA

• SESSION 12: EVOLUTION IN CANCER PREVENTION, EPITHELIAL-MESENCHYNAL TRANSITION, AND CARCINOGENESIS
  Chairperson: Carlo C. Maley, The Wistar Institute, Philadelphia, PA
  
  Clonal Evolution Over Time in Barrett's Esophagus
  Carlo C. Maley
  
  Evolution in Carcinogenesis
  Darryl K. Shibata, University of Southern California, Los Angeles, CA
  
  Molecular Definition of EMT in Human Breast Cancer Cell Lines and Purified Breast Cancer Stem Cells
  Erik W. Thompson, University of Melbourne, Fitzroy, Australia

PLENARY SESSION 4: COMMUNICATION CENTERS / CANCER PREVENTION

Chairperson: David H. Gustafson, University of Wisconsin, Madison, WI
3:00 p.m.-5:00 p.m.

Title to be announced
David H. Gustafson

Title to be announced
Robert C. Hornik, University of Pennsylvania, Philadelphia, PA

Additional Speakers to be announced

POSTER SESSION B

5:00 p.m.-7:30 p.m.

PLENARY SESSION 5: INTEGRATIVE PREVENTION

Chairperson: Ernest T. Hawk, UT M.D. Anderson Cancer Center, Houston, TX
8:00 a.m.-10:00 a.m.

Speakers to be announced

CONCURRENT SESSIONS

10:15 a.m.-12:00 p.m.

• SESSION 13: BREAST CANCER
  Chairperson: Thea D. Tlsty, UCSF School of Medicine, San Francisco, CA

  
  Molecular Markers that Predict Future Formation of Malignant Breast Cancer
  Thea D. Tlsty

  Breast Tissue Composition and Risk of Breast Cancer
  Norman F. Boyd, Ontario Cancer Institute, Toronto, ON, Canada
  
  Intraductal Route of Breast Cancer Prevention and Therapy: From Preclinical Studies to Phase I Trials
  Saraswati Sukumar, Johns Hopkins University, Baltimore, MD

• SESSION 14: LUNG CANCER PREVENTION
  Chairperson: Jenny T. Mao, David Geffen School of Medicine at UCLA, Los Angeles, CA

  
  A Genome-wide Association Study Identifies Variation in Nicotine Acetylcholine Receptors that Influence Risk for Lung Cancer and Smoking Behavior
  Christopher I. Amos, UT M.D. Anderson Cancer Center, Houston, TX

  Proteomics Strategies for Lung Cancer Diagnostics
  Pierre P. Massion, Vanderbilt University, Nashville, TN

  Lung Cancer Chemoprevention with Celecoxib
  Jenny T. Mao
  

• SESSION 15: COLORECTAL CANCER PREVENTION - INFLAMMATION, INFECTION, AND IMMUNITY
  Chairperson: Andrew T. Chan, Massachusetts General Hospital, Boston, MA
  
  Aspirin, COX-2, and Colorectal Cancer
  Andrew T. Chan
  
  Gut Microbiota and Colorectal Adenoma
  Temitope Keku, University of North Carolina, Chapel Hill, NC
  
  Additional Speaker to be announced

DEPARTURE